| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4878153
Max Phase: Preclinical
Molecular Formula: C16H17ClN4O2S
Molecular Weight: 364.86
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1nc([C@@H](CN)NC(=O)c2cc3cc(Cl)ccc3[nH]2)sc1CO
Standard InChI: InChI=1S/C16H17ClN4O2S/c1-8-14(7-22)24-16(19-8)13(6-18)21-15(23)12-5-9-4-10(17)2-3-11(9)20-12/h2-5,13,20,22H,6-7,18H2,1H3,(H,21,23)/t13-/m1/s1
Standard InChI Key: VHNPCDRDZCXODT-CYBMUJFWSA-N
Associated Targets(Human)
TZM 838 Activities
Associated Targets(non-human)
Envelope glycoprotein gp160 755 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 364.86 | Molecular Weight (Monoisotopic): 364.0761 | AlogP: 2.51 | #Rotatable Bonds: 5 |
| Polar Surface Area: 104.03 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 13.76 | CX Basic pKa: 8.37 | CX LogP: 1.04 | CX LogD: 0.03 |
| Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.56 | Np Likeness Score: -1.26 |
References
| 1. Iusupov IR, Curreli F, Spiridonov EA, Markov PO, Ahmed S, Belov DS, Manasova EV, Altieri A, Kurkin AV, Debnath AK.. (2021) Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements., 224 [PMID:34246921] [10.1016/j.ejmech.2021.113681] |
Source
Source(1):